Symbols / NBIX Stock $154.37 +2.51% Neurocrine Biosciences, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
NBIX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Kyle W. Gano Ph.D.
Exch · Country NMS · United States
Market Cap 15.52B
Enterprise Value 14.29B
Income 668.60M
Sales 3.10B
FCF (ttm) 590.55M
Book/sh 32.50
Cash/sh 13.09
Employees 2,000
Insider 10d —
IPO May 23, 1996
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 23.79
Forward P/E 12.15
PEG 0.43
P/S 5.00
P/B 4.75
P/C —
EV/EBITDA 17.25
EV/Sales 4.61
Quick Ratio 2.51
Current Ratio 2.93
Debt/Eq 13.60
LT Debt/Eq —
EPS (ttm) 6.49
EPS next Y 12.71
EPS Growth 23.11%
Revenue Growth 42.20%
EPS Gr Q/Q 24.05%
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-05-05
ROA 11.62%
ROE 22.50%
ROIC —
Gross Margin 64.37%
Oper. Margin 22.84%
Profit Margin 21.55%
Shs Outstand 100.55M
Shs Float 99.26M
Insider Own 1.10%
Instit Own 100.47%
Short Float 7.76%
Short Ratio 5.14
Short Interest 5.99M
52W High 160.18
vs 52W High -3.63%
52W Low 116.00
vs 52W Low 33.08%
Beta 0.34
Impl. Vol. 67.57%
Rel Volume 0.30
Avg Volume 1.15M
Volume 349.16K
Target (mean) $190.99
Tgt Median $186.00
Tgt Low $144.00
Tgt High $250.65
# Analysts 27
Recom Strong_buy
Prev Close $150.59
Price $154.37
Change 2.51%
About

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$190.99
Mean price target
2. Current target
$154.37
Latest analyst target
3. DCF / Fair value
$105.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$154.37
Low
$144.00
High
$250.65
Mean
$190.99

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main JP Morgan Overweight → Overweight $185
2026-05-07 main Truist Securities Buy → Buy $155
2026-05-06 main Citigroup Buy → Buy $246
2026-05-06 main Morgan Stanley Equal-Weight → Equal-Weight $191
2026-05-06 main RBC Capital Outperform → Outperform $180
2026-05-06 main Piper Sandler Overweight → Overweight $207
2026-05-06 reit Guggenheim Buy → Buy $175
2026-05-06 main Wedbush Outperform → Outperform $176
2026-04-22 main Leerink Partners Outperform → Outperform $170
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $185
2026-04-07 main Citigroup Buy → Buy $242
2026-04-07 main Canaccord Genuity Buy → Buy $200
2026-04-07 main Wedbush Outperform → Outperform $166
2026-04-07 main HC Wainwright & Co. Buy → Buy $215
2026-04-06 reit Needham Buy → Buy $185
2026-03-12 main JP Morgan Overweight → Overweight $177
2026-02-24 init Wolfe Research — → Outperform $160
2026-02-17 main JP Morgan Overweight → Overweight $176
2026-02-17 main Truist Securities Buy → Buy $140
2026-02-13 main Wells Fargo Overweight → Overweight $175
News
RSS: Latest NBIX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 ABERNETHY MATTHEW C Chief Financial Officer — 2,249 $0.00 $0
2026-02-20 ONYIA JUDE Officer — 3,110 $0.00 $0
2026-02-13 GORMAN KEVIN CHARLES Director — 63,724 $0.00 $0
2026-02-13 GORMAN KEVIN CHARLES Director — 10,981 — —
2026-02-13 LIPPOLDT DARIN M Officer — 9,968 $0.00 $0
2026-02-13 LIPPOLDT DARIN M Officer — 365 $0.00 $0
2026-02-13 LIPPOLDT DARIN M Officer — 5,892 — —
2026-02-13 GANO KYLE W Chief Executive Officer — 9,968 $0.00 $0
2026-02-13 GANO KYLE W Chief Executive Officer — 9,714 — —
2026-02-13 BENEVICH ERIC S. Officer — 16,613 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,860.50
+21.45%
2,355.30
+24.81%
1,887.10
+26.76%
1,488.70
Operating Revenue
2,860.50
+21.45%
2,355.30
+24.81%
1,887.10
+26.76%
1,488.70
Cost Of Revenue
52.10
+53.24%
34.00
-14.36%
39.70
+71.12%
23.20
Reconciled Cost Of Revenue
52.10
+53.24%
34.00
-14.36%
39.70
+71.12%
23.20
Gross Profit
2,808.40
+20.98%
2,321.30
+25.65%
1,847.40
+26.06%
1,465.50
Operating Expense
2,171.90
+24.94%
1,738.30
+19.67%
1,452.60
+19.41%
1,216.50
Research And Development
1,015.70
+38.93%
731.10
+29.40%
565.00
+21.82%
463.80
Selling General And Administration
1,156.20
+14.79%
1,007.20
+13.47%
887.60
+17.92%
752.70
Total Expenses
2,224.00
+25.49%
1,772.30
+18.76%
1,492.30
+20.38%
1,239.70
Operating Income
636.50
+9.18%
583.00
+47.67%
394.80
+58.55%
249.00
Total Operating Income As Reported
619.10
+8.52%
570.50
+127.38%
250.90
+0.76%
249.00
EBITDA
666.60
+4.21%
639.70
+53.74%
416.10
+57.26%
264.60
Normalized EBITDA
688.00
-1.87%
701.10
+31.88%
531.60
+74.98%
303.80
Reconciled Depreciation
30.10
+11.07%
27.10
+27.23%
21.30
+36.54%
15.60
EBIT
636.50
+3.90%
612.60
+55.17%
394.80
+58.55%
249.00
Total Unusual Items
-21.40
+65.15%
-61.40
+46.84%
-115.50
-194.64%
-39.20
Total Unusual Items Excluding Goodwill
-21.40
+65.15%
-61.40
+46.84%
-115.50
-194.64%
-39.20
Special Income Charges
-17.40
-18.37%
-14.70
+89.78%
-143.90
-105.57%
-70.00
Other Special Charges
17.40
+18.37%
14.70
-89.78%
143.90
+105.57%
70.00
Net Income
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Pretax Income
705.40
+45.14%
486.00
+46.34%
332.10
+55.26%
213.90
Net Non Operating Interest Income Expense
90.30
+353.65%
-35.60
-167.42%
52.80
+1187.80%
4.10
Interest Expense Non Operating
—
126.60
+2652.17%
4.60
-35.21%
7.10
Net Interest Income
90.30
+353.65%
-35.60
-167.42%
52.80
+1187.80%
4.10
Interest Expense
—
126.60
+2652.17%
4.60
-35.21%
7.10
Interest Income Non Operating
90.30
-0.77%
91.00
+72.35%
52.80
+1187.80%
4.10
Interest Income
90.30
-0.77%
91.00
+72.35%
52.80
+1187.80%
4.10
Other Income Expense
-21.40
+65.15%
-61.40
+46.84%
-115.50
-194.64%
-39.20
Gain On Sale Of Security
-4.00
+91.43%
-46.70
-264.44%
28.40
-7.79%
30.80
Tax Provision
226.80
+56.74%
144.70
+75.61%
82.40
+38.72%
59.40
Tax Rate For Calcs
0.00
+7.99%
0.00
+20.00%
0.00
-10.65%
0.00
Tax Effect Of Unusual Items
-6.88
+62.36%
-18.28
+36.21%
-28.66
-163.26%
-10.89
Net Income Including Noncontrolling Interests
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Net Income From Continuing Operation Net Minority Interest
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Net Income From Continuing And Discontinued Operation
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Net Income Continuous Operations
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Normalized Income
493.12
+28.28%
384.42
+14.23%
336.54
+84.09%
182.81
Net Income Common Stockholders
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Diluted EPS
4.67
+41.95%
3.29
+33.20%
2.47
+58.33%
1.56
Basic EPS
4.81
+41.47%
3.40
+32.81%
2.56
+59.01%
1.61
Basic Average Shares
99.50
-0.90%
100.40
+2.76%
97.70
+1.98%
95.80
Diluted Average Shares
102.50
-1.16%
103.70
+2.67%
101.00
+2.12%
98.90
Diluted NI Availto Com Stockholders
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
4,631.50
+24.55%
3,718.70
+14.37%
3,251.40
+37.27%
2,368.70
Current Assets
2,522.70
+46.27%
1,724.70
+7.32%
1,607.00
+10.56%
1,453.50
Cash Cash Equivalents And Short Term Investments
1,480.40
+37.57%
1,076.10
+4.31%
1,031.60
+4.28%
989.30
Cash And Cash Equivalents
713.00
+206.01%
233.00
-7.21%
251.10
-4.49%
262.90
Other Short Term Investments
767.40
-8.98%
843.10
+8.02%
780.50
+7.45%
726.40
Receivables
686.80
+43.35%
479.10
+9.06%
439.30
+25.51%
350.00
Accounts Receivable
686.80
+43.35%
479.10
+9.06%
439.30
+25.51%
350.00
Inventory
69.00
+20.21%
57.40
+49.87%
38.30
+9.12%
35.10
Raw Materials
35.70
+5.93%
33.70
+56.74%
21.50
+79.17%
12.00
Work In Process
19.20
+76.15%
10.90
+12.37%
9.70
+73.21%
5.60
Finished Goods
14.30
+11.72%
12.80
+4.07%
12.30
-29.71%
17.50
Prepaid Assets
170.70
+251.96%
48.50
—
—
Other Current Assets
115.80
+82.08%
63.60
-34.97%
97.80
+23.64%
79.10
Total Non Current Assets
2,108.80
+5.76%
1,994.00
+21.26%
1,644.40
+79.68%
915.20
Net PPE
545.20
-7.91%
592.00
+70.46%
347.30
+138.53%
145.60
Gross PPE
663.50
-5.01%
698.50
+62.33%
430.30
+103.07%
211.90
Accumulated Depreciation
-118.30
-11.08%
-106.50
-28.31%
-83.00
-25.19%
-66.30
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
49.20
-14.43%
57.50
+59.28%
36.10
+28.01%
28.20
Other Properties
578.70
-4.36%
605.10
+69.92%
356.10
+144.24%
145.80
Leases
35.60
-0.84%
35.90
-5.77%
38.10
+0.53%
37.90
Goodwill And Other Intangible Assets
—
36.50
+2.82%
35.50
-4.57%
37.20
Other Intangible Assets
—
36.50
+2.82%
35.50
-4.57%
37.20
Investments And Advances
1,183.80
+36.97%
864.30
+1.75%
849.40
+111.56%
401.50
Non Current Deferred Assets
320.30
-34.05%
485.70
+33.95%
362.60
+18.54%
305.90
Non Current Deferred Taxes Assets
320.30
-34.05%
485.70
+33.95%
362.60
+18.54%
305.90
Other Non Current Assets
59.50
+14.42%
52.00
+4.84%
49.60
+98.40%
25.00
Total Liabilities Net Minority Interest
1,378.40
+22.09%
1,129.00
+10.75%
1,019.40
+54.24%
660.90
Current Liabilities
743.40
+46.43%
507.70
-22.46%
654.80
+21.78%
537.70
Payables And Accrued Expenses
319.50
+52.22%
209.90
-6.00%
223.30
+56.26%
142.90
Payables
172.90
+57.32%
109.90
-17.55%
133.30
+74.71%
76.30
Accounts Payable
104.90
+5.01%
99.90
-25.06%
133.30
+98.07%
67.30
Current Accrued Expenses
146.60
+46.60%
100.00
+11.11%
90.00
+35.14%
66.60
Pensionand Other Post Retirement Benefit Plans Current
128.80
+19.81%
107.50
+24.71%
86.20
+18.41%
72.80
Total Tax Payable
68.00
+580.00%
10.00
-59.02%
24.40
+171.11%
9.00
Income Tax Payable
68.00
+580.00%
10.00
-59.02%
24.40
+171.11%
9.00
Current Debt And Capital Lease Obligation
—
—
170.10
+0.41%
169.40
Current Debt
—
—
170.10
+0.41%
169.40
Other Current Borrowings
—
—
170.10
+0.41%
169.40
Other Current Liabilities
69.10
+49.89%
46.10
+28.41%
35.90
+73.43%
20.70
Total Non Current Liabilities Net Minority Interest
635.00
+2.21%
621.30
+70.41%
364.60
+195.94%
123.20
Long Term Debt And Capital Lease Obligation
415.30
-8.75%
455.10
+76.19%
258.30
+176.26%
93.50
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
415.30
-8.75%
455.10
+76.19%
258.30
+176.26%
93.50
Tradeand Other Payables Non Current
214.50
+33.48%
160.70
+67.40%
96.00
+384.85%
19.80
Other Non Current Liabilities
5.20
-5.45%
5.50
-46.60%
10.30
+4.04%
9.90
Stockholders Equity
3,253.10
+25.62%
2,589.70
+16.03%
2,232.00
+30.69%
1,707.80
Common Stock Equity
3,253.10
+25.62%
2,589.70
+16.03%
2,232.00
+30.69%
1,707.80
Capital Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Common Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
100.10
+0.70%
99.40
+0.71%
98.70
+2.28%
96.50
Ordinary Shares Number
100.10
+0.70%
99.40
+0.71%
98.70
+2.28%
96.50
Additional Paid In Capital
2,792.20
+9.30%
2,554.60
+7.25%
2,382.00
+12.23%
2,122.40
Retained Earnings
447.70
+1433.22%
29.20
+118.59%
-157.10
+61.38%
-406.80
Gains Losses Not Affecting Retained Earnings
13.10
+125.86%
5.80
-17.14%
7.00
+188.61%
-7.90
Other Equity Adjustments
13.10
+125.86%
5.80
-17.14%
7.00
+188.61%
-7.90
Total Equity Gross Minority Interest
3,253.10
+25.62%
2,589.70
+16.03%
2,232.00
+30.69%
1,707.80
Total Capitalization
3,253.10
+25.62%
2,589.70
+16.03%
2,232.00
+30.69%
1,707.80
Working Capital
1,779.30
+46.20%
1,217.00
+27.81%
952.20
+3.97%
915.80
Invested Capital
3,253.10
+25.62%
2,589.70
+7.81%
2,402.10
+27.96%
1,877.20
Total Debt
415.30
-8.75%
455.10
+6.23%
428.40
+62.95%
262.90
Capital Lease Obligations
415.30
-8.75%
455.10
+76.19%
258.30
+176.26%
93.50
Net Tangible Assets
3,253.10
+25.62%
2,589.70
+17.90%
2,196.50
+31.48%
1,670.60
Tangible Book Value
3,253.10
+25.62%
2,589.70
+17.90%
2,196.50
+31.48%
1,670.60
Available For Sale Securities
1,183.80
+36.97%
864.30
+1.75%
849.40
+111.56%
401.50
Current Provisions
226.00
+56.73%
144.20
+3.52%
139.30
+5.61%
131.90
Inventories Adjustments Allowances
-0.20
0.00
+100.00%
-5.20
0.00
Investmentin Financial Assets
1,183.80
+36.97%
864.30
+1.75%
849.40
+111.56%
401.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
782.70
+31.46%
595.40
+52.71%
389.90
+14.88%
339.40
Cash Flow From Continuing Operating Activities
782.70
+31.46%
595.40
+52.71%
389.90
+14.88%
339.40
Net Income From Continuing Operations
478.60
+40.23%
341.30
+36.68%
249.70
+61.62%
154.50
Depreciation Amortization Depletion
30.10
+11.07%
27.10
+27.23%
21.30
+36.54%
15.60
Depreciation
26.00
+10.64%
23.50
+32.02%
17.80
+17.88%
15.10
Amortization Cash Flow
4.10
+13.89%
3.60
+2.86%
3.50
+600.00%
0.50
Depreciation And Amortization
30.10
+11.07%
27.10
+27.23%
21.30
+36.54%
15.60
Amortization Of Intangibles
4.10
+13.89%
3.60
+2.86%
3.50
+600.00%
0.50
Other Non Cash Items
14.80
-87.94%
122.70
+763.24%
-18.50
-125.84%
71.60
Stock Based Compensation
217.90
+11.46%
195.50
+0.62%
194.30
+12.25%
173.10
Asset Impairment Charge
0.70
-95.00%
14.00
0.00
—
Deferred Tax
165.40
+234.36%
-123.10
-117.11%
-56.70
-396.86%
19.10
Deferred Income Tax
165.40
+234.36%
-123.10
-117.11%
-56.70
-396.86%
19.10
Operating Gains Losses
—
—
—
70.00
Unrealized Gain Loss On Investment Securities
4.00
-89.22%
37.10
+230.63%
-28.40
+7.79%
-30.80
Change In Working Capital
-128.80
-570.83%
-19.20
-168.09%
28.20
+141.84%
-67.40
Change In Receivables
-210.50
-428.89%
-39.80
+55.43%
-89.30
+44.94%
-162.20
Changes In Account Receivables
-210.50
-428.89%
-39.80
+55.43%
-89.30
+44.94%
-162.20
Change In Inventory
-15.30
+19.90%
-19.10
-453.70%
5.40
+307.69%
-2.60
Change In Payables And Accrued Expense
160.20
+269.12%
43.40
-11.43%
49.00
-57.24%
114.60
Change In Other Working Capital
-63.20
-1608.11%
-3.70
-105.86%
63.10
+466.86%
-17.20
Investing Cash Flow
-264.40
-108.52%
-126.80
+72.85%
-467.10
-163.75%
-177.10
Cash Flow From Continuing Investing Activities
-264.40
-108.52%
-126.80
+72.85%
-467.10
-163.75%
-177.10
Net PPE Purchase And Sale
—
—
—
—
Purchase Of PPE
—
—
—
—
Capital Expenditure
-34.00
+10.99%
-38.20
-34.98%
-28.30
-71.52%
-16.50
Capital Expenditure Reported
-34.00
+10.99%
-38.20
-34.98%
-28.30
-71.52%
-16.50
Net Investment Purchase And Sale
-230.40
-160.05%
-88.60
+79.81%
-438.80
-272.18%
-117.90
Purchase Of Investment
-1,319.80
-24.97%
-1,056.10
+25.16%
-1,411.20
-124.39%
-628.90
Sale Of Investment
1,089.40
+12.60%
967.50
-0.50%
972.40
+90.29%
511.00
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-42.70
Purchase Of Business
—
0.00
0.00
+100.00%
-42.70
Financing Cash Flow
-38.30
+92.13%
-486.70
-845.33%
65.30
+127.87%
-234.30
Cash Flow From Continuing Financing Activities
-38.30
+92.13%
-486.70
-845.33%
65.30
+127.87%
-234.30
Net Issuance Payments Of Debt
0.00
+100.00%
-308.80
0.00
+100.00%
-279.00
Repayment Of Debt
0.00
+100.00%
-308.80
0.00
+100.00%
-279.00
Long Term Debt Payments
0.00
+100.00%
-308.80
0.00
+100.00%
-279.00
Net Long Term Debt Issuance
0.00
+100.00%
-308.80
0.00
+100.00%
-279.00
Short Term Debt Payments
—
-308.80
0.00
+100.00%
-279.00
Net Short Term Debt Issuance
—
-308.80
0.00
+100.00%
-279.00
Net Common Stock Issuance
-167.70
+44.10%
-300.00
0.00
0.00
Common Stock Payments
-167.70
+44.10%
-300.00
0.00
0.00
Repurchase Of Capital Stock
-167.70
+44.10%
-300.00
0.00
0.00
Proceeds From Stock Option Exercised
129.40
+5.98%
122.10
+86.98%
65.30
+46.09%
44.70
Changes In Cash
480.00
+2751.93%
-18.10
-52.10%
-11.90
+83.47%
-72.00
Effect Of Exchange Rate Changes
0.00
0.00
-100.00%
0.30
+123.08%
-1.30
Beginning Cash Position
241.00
-6.99%
259.10
-4.29%
270.70
-21.31%
344.00
End Cash Position
721.00
+199.17%
241.00
-6.99%
259.10
-4.29%
270.70
Free Cash Flow
748.70
+34.37%
557.20
+54.09%
361.60
+11.99%
322.90
Interest Paid Supplemental Data
0.00
-100.00%
1.60
-57.89%
3.80
-42.42%
6.60
Income Tax Paid Supplemental Data
81.40
-62.57%
217.50
+322.33%
51.50
+257.64%
14.40
Amortization Of Securities
—
-26.20
-43.17%
-18.30
-594.59%
3.70
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category